A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples